AstraZeneca poaches Roche executive for chief medical officer role
24th Aug 2015 07:32
(ShareCast News) - AstraZeneca has hired an executive from Roche subsidiary Genentech to join as executive vice president of global medicines development and chief medical officer. The pharmaceutical company said in a release Sean Bohen would join from 15 September. Bohen will be in charge of Astra
Read moreAstraZeneca to pay Inovio up to $700m for cancer vaccine
10th Aug 2015 11:48
(ShareCast News) - AstraZeneca has entered into an agreement to buy the rights to an experimental cancer drug from Inovio Pharmaceuticals for up to $700m. Under the terms of the agreement, MedImmune - Astra's global biologics research and development arm - will acquire exclusive rights to Inovio's I
Read moreAstraZeneca signs $500m immuno-oncology deal with Heptares
6th Aug 2015 09:27
(ShareCast News) - Pharmaceutical giant AstraZeneca has signed a $500m deal to strengthen its position in the hot area of immuno-oncology with Japanese giant Sosei. The agreement with Sosei's subsidiary Heptares gives Astrazeneca the licence to acquire exclusive global rights to develop, manufacture
Read moreLondon close: Stocks end higher despite Fed decision
30th Jul 2015 18:00
(ShareCast News) - London share prices ended modestly higher despite the US Federal Reserve's decision to leave the door open to possible interest rate increases in September which, it must be pointed out, might add to the pressure on the Bank of England to also make a move soon. The Footsie ended t
Read moreFTSE 100 movers: Shell rallies on better-than-expected earnings, but Centrica drops after announcing job cuts
30th Jul 2015 15:56
(ShareCast News) - London's top-flight index was up 0.6% at 6,670 by 15:41 BST, as investors waded through a raft of earnings reports. Royal Dutch Shell and BG Group were both sharply higher after Shell's second-quarter results beat expectations. The Anglo-Dutch oil major posted adjusted profits of
Read moreLondon midday: Heavyweight corporate earnings lift FTSE 100
30th Jul 2015 12:37
(ShareCast News) - London share prices remained mostly in positive territory by midday on Thursday, as strong corporate results from heavyweights in various sectors, notably Shell, RBS and Astrazeneca, combined with a stronger oil price. At 12:15 the FTSE was up 0.79% to 6,683.11, almost recapturing
Read moreAstraZeneca's second-quarter earnings beat expectations; lifts sales guidance
30th Jul 2015 08:12
(ShareCast News) - AstraZeneca's second-quarter earnings beat expectations as generic competition and the effects of a stronger US dollar were offset by the spinning off of assets and a good performance from the company's Brillinta drug. The pharmaceuticals giant posted core operating profit of $1.8
Read moreThursday preview: Busy day of earnings await with flood of FTSE 350 interims
29th Jul 2015 15:48
(ShareCast News) - Investors will on Thursday be snowed under with earnings from a batch of FTSE 350 companies. Astrazeneca, Weir Group and Royal Dutch Shell will be among those reporting. Shell will be hoping to outperform BP in its second quarter results. BP on Tuesday reported a 64% drop in quar
Read moreAstraZeneca sells cancer drug to Sanofi for $300m
27th Jul 2015 08:45
(ShareCast News) - AstraZeneca has entered into a definitive agreement with Sanofi's rare diseases unit, Genzyme, to divest Caprelsa, which is used to treat a rare type of cancer. Under the terms of the deal, Genzyme will pay up to $300m to AstraZeneca, including an upfront payment of $165m to acqui
Read moreAstraZeneca divests international gastroenterolgy drug rights to Tillotts Pharma
17th Jul 2015 08:41
(ShareCast News) - Pharmaceuticals giant AstraZeneca has completed its agreement with Tillotts Pharma, part of the Zeria Group, for the divestment of global rights outside the US, to Entocort, which is a gastroenterology medicine for patients with mild to moderate Crohn's disease and ulcerative coli
Read moreFTSE 100 movers: Meggitt surges on merger mumbles, Carney chat hits housebuilders
14th Jul 2015 14:29
(ShareCast News) - London markets edged lower on Tuesday, as losses from housebuilders, engineers and financials eclipsed gains made by industrial metals. As of 14:00 BST, the FTSE 100 was trading 0.2% lower at 6,727. Shares in defence and aerospace engineer Meggitt rose following a report in the F
Read moreLondon midday: Homebuilders knocked lower by remarks from Carney
14th Jul 2015 13:09
(ShareCast News) - Bank of England Governor Mark Carney told the Treasury Select Committee Bank Rate may be headed higher a little bit sooner than markets anticipated, sending stocks - especially homebuilders - listed on the second tier index promptly lower. As of 12:13 the top flight index was off
Read moreMonday broker round-up
13th Jul 2015 12:05
(ShareCast News) - ARM Holdings: JP Morgan downgrades to underweight and lowers target to 900p from 950p; Exane reiterates outperform with 1,400p target. AstraZeneca: Goldman Sachs stays at neutral and Jefferies at buy. British American Tobacco: Nomura starts coverage at buy with 3,920p target. Bu
Read moreAstrazeneca offloads Crohn's treatment for $215m
9th Jul 2015 09:01
Astrazeneca has sold global rights outside the US for its Entocort medicine, which treats Crohn's disease and ulcerative colitis, to Japan's Zeria Group for $215m Entocort generated product sales of $53m outside the US in 2014 for the FTSE 100 drug group, which said the disposal to Zeria subsidiary
Read moreFTSE 100 movers: Defensives gain, miners sold off as risk appetite wanes
7th Jul 2015 15:16
Defensive sectors such as real estate and pharmaceuticals were performing well while commodity stocks were falling on Tuesday, with investors reducing their appetite for risk as European leaders met in Brussels to discuss Greece's future. Stocks which tend to hold up better in times of economic inst
Read more